+86-28-82633987
ISO ISO
ISO 17025 ISO 17025
usp usp
EN
CN EN

Jatrorrhizine

BP0808
3621-38-3
98%
Phytopurify
Mahoniae Caulis
Jatrorrhizine has neuroprotective, antioxidative, anti-inflammatory, antihypercholesterolemic, and anti-hyperglycemia effects.Jatrorrhizine is expected to be developed as a new gastric prokinetic drug, it is metabolized by human CYP1A2 and multiple UGT1A isoforms. It has inhibitory activities against the expression of inducible NO syntase (iNOS) and cyclooxygenase-2 (COX-2), and can improve the utilization and excretion of cholesterol by up-regulating the mRNA and protein expression of LDLR and CYP7A1.
Catalog No Package Original Price Price Inventory Quantity Operating
BP0808-100mg 100mg
BP0808-1000mg 1000mg
Chengdu Biopurify Phytochemicals Ltd.
Chengdu Biopurify Phytochemicals Ltd.

Related diseases

Related targets

GYRA GYPB DHFR MECA PENA

Product drug property prediction parameters

  • 51.8000

  • .5732

  • .5219

  • .4907

  • 1.0052

  • 15.1231

  • Low

  • 41.1612

  • 2.7399

  • Yes

  • No

  • No

  • No

  • Yes

  • Yes

  • 0.9

  • No

  • No

  • No

  • No

Jatrorrhizine Reference LiteratureMORE+